Related Experiment Video
Updated: Feb 14, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
Antisense oligonucleotides and other genetic therapies made simple
Alexander M Rossor1,2, Mary M Reilly1, James N Sleigh2
1MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK.
Abstract:
Many genetic neurological diseases result from the dysfunction of single proteins. Genetic therapies aim to modify these disease-associated proteins by targeting the RNA and DNA precursors. This review provides a brief overview of the main types of genetic therapies, with a focus on antisense oligonucleotides (ASOs) and RNA interference (RNAi). We use examples of new genetic therapies for spinal muscular atrophy, Duchenne muscular dystrophy and familial amyloid polyneuropathy to highlight the different mechanisms of action of ASOs and RNAi.
Related Concept Videos
What is Genetic Engineering?
Genetics of Speciation
What is Population Genetics?
Gene Therapy
Animal Mitochondrial Genetics
Group Therapy

